Breaking News
May 3, 2019 - Vaping and Smoking May Signal Greater Motivation to Quit
May 3, 2019 - Dementia looks different in brains of Hispanics
May 3, 2019 - Short-Staffed Nursing Homes See Drop In Medicare Ratings
May 3, 2019 - Study of teens with eating disorders explores how substance users differ from non-substance users
May 3, 2019 - Scientists develop new video game that may help in the study of Alzheimer’s
May 3, 2019 - Arc Bio introduces Galileo Pathogen Solution product line at ASM Clinical Virology Symposium
May 3, 2019 - Cornell University study uncovers relationship between starch digestion gene and gut bacteria
May 3, 2019 - How to Safely Use Glucose Meters and Test Strips for Diabetes
May 3, 2019 - Anti-inflammatory drugs ineffective for prevention of Alzheimer’s disease
May 3, 2019 - Study tracks Pennsylvania’s oil and gas waste-disposal practices
May 3, 2019 - Creating a better radiation diagnostic test for astronauts
May 3, 2019 - Vegans are often deficient in these four nutrients
May 3, 2019 - PPDC announces seed grants to develop medical devices for children
May 3, 2019 - Study maps out the frequency and impact of water polo head injuries
May 3, 2019 - Research on Reddit identifies risks associated with unproven treatments for opioid addiction
May 3, 2019 - Good smells may help ease tobacco cravings
May 3, 2019 - Medical financial hardship found to be very common among people in the United States
May 3, 2019 - Researchers develop multimodal system for personalized post-stroke rehabilitation
May 3, 2019 - Study shows significant mortality benefit with CABG over percutaneous coronary intervention
May 3, 2019 - Will gene-editing of human embryos ever be justifiable?
May 3, 2019 - FDA Approves Dengvaxia (dengue vaccine) for the Prevention of Dengue Disease in Endemic Regions
May 3, 2019 - Why Tonsillitis Keeps Coming Back
May 3, 2019 - Fighting the opioid epidemic with data
May 3, 2019 - Maggot sausages may soon be a reality
May 3, 2019 - Deletion of ATDC gene prevents development of pancreatic cancer in mice
May 2, 2019 - Targeted Therapy Promising for Rare Hematologic Cancer
May 2, 2019 - Alzheimer’s disease is a ‘double-prion disorder,’ study shows
May 2, 2019 - Reservoir bugs: How one bacterial menace makes its home in the human stomach
May 2, 2019 - Clinical, Admin Staff From Cardiology Get Sneak Peek at Epic
May 2, 2019 - Depression increases hospital use and mortality in children
May 2, 2019 - Vicon and NOC support CURE International to create first gait lab in Ethiopia
May 2, 2019 - Researchers use 3D printer to make paper organs
May 2, 2019 - Viral infection in utero associated with behavioral abnormalities in offspring
May 2, 2019 - U.S. Teen Opioid Deaths Soaring
May 2, 2019 - Opioid distribution data should be public
May 2, 2019 - In the Spotlight: “I’m learning every single day”
May 2, 2019 - 2019 Schaefer Scholars Announced
May 2, 2019 - Podcast: KHN’s ‘What The Health?’ Bye-Bye, ACA, And Hello ‘Medicare-For-All’?
May 2, 2019 - Study describes new viral molecular evasion mechanism used by cytomegalovirus
May 2, 2019 - SLU study suggests a more equitable way for Medicare reimbursement
May 2, 2019 - Scientists discover first gene involved in lower urinary tract obstruction
May 2, 2019 - Researchers identify 34 genes associated with increased risk of ovarian cancer
May 2, 2019 - Many low-income infants receive formula in the first few days of life, finds study
May 2, 2019 - Global study finds high success rate for hip and knee replacements
May 2, 2019 - Taking depression seriously: What is it?
May 2, 2019 - With Head Injuries Mounting, Will Cities Put Their Feet Down On E-Scooters?
May 2, 2019 - Scientists develop small fluorophores for tracking metabolites in living cells
May 2, 2019 - Study casts new light into how mothers’ and babies’ genes influence birth weight
May 2, 2019 - Researchers uncover new brain mechanisms regulating body weight
May 2, 2019 - Organ-on-chip systems offered to Asia-Pacific regions by Sydney’s AXT
May 2, 2019 - Adoption of new rules drops readmission penalties against safety net hospitals
May 2, 2019 - Kids and teens who consume zero-calorie sweetened beverages do not save calories
May 2, 2019 - Improved procedure for cancer-related erectile dysfunction
May 2, 2019 - Hormone may improve social behavior in autism
May 2, 2019 - Alzheimer’s disease may be caused by infectious proteins called prions
May 2, 2019 - Even Doctors Can’t Navigate Our ‘Broken Health Care System’
May 2, 2019 - Study looks at the impact on criminal persistence of head injuries
May 2, 2019 - Honey ‘as high in sugars as table sugar’
May 2, 2019 - Innovations to U.S. food system could help consumers in choosing healthy foods
May 2, 2019 - FDA Approves Mavyret (glecaprevir and pibrentasvir) as First Treatment for All Genotypes of Hepatitis C in Pediatric Patients
May 2, 2019 - Women underreport prevalence and intensity of their own snoring
May 2, 2019 - Concussion summit focuses on science behind brain injury
May 2, 2019 - Booker’s Argument For Environmental Justice Stays Within The Lines
May 2, 2019 - Cornell research explains increased metastatic cancer risk in diabetics
May 2, 2019 - Mount Sinai study provides fresh insights into cellular pathways that cause cancer
May 2, 2019 - Researchers to study link between prenatal pesticide exposures and childhood ADHD
May 2, 2019 - CoGEN Congress 2019: Speakers’ overviews
May 2, 2019 - A new strategy for managing diabetic macular edema in people with good vision
May 2, 2019 - Sagent Pharmaceuticals Issues Voluntary Nationwide Recall of Ketorolac Tromethamine Injection, USP, 60mg/2mL (30mg per mL) Due to Lack of Sterility Assurance
May 2, 2019 - Screen time associated with behavioral problems in preschoolers
May 2, 2019 - Hormone reduces social impairment in kids with autism | News Center
May 2, 2019 - Researchers synthesize peroxidase-mimicking nanozyme with low cost and superior catalytic activity
May 2, 2019 - Study results of a potential drug to treat Type 2 diabetes in children announced
May 2, 2019 - Multigene test helps doctors to make effective treatment decisions for breast cancer patients
May 2, 2019 - UNC School of Medicine initiative providing unique care to dementia patients
May 2, 2019 - Nestlé Health Science and VHP join forces to launch innovative COPES program for cancer patients
May 2, 2019 - Study examines how our brain generates consciousness and loses it during anesthesia
May 2, 2019 - Transition Support Program May Aid Young Adults With Type 1 Diabetes
May 2, 2019 - Study shows how neutrophils exacerbate atherosclerosis by inducing smooth muscle-cell death
May 2, 2019 - Research reveals complexity of how we make decisions
Goodbye ‘Gluten-Free’? Celiac Disease Vaccine May Make It Possible

Goodbye ‘Gluten-Free’? Celiac Disease Vaccine May Make It Possible

WEDNESDAY, Nov. 14, 2018 — People with celiac disease must follow a very restrictive diet, but an experimental vaccine may offer many of them the freedom to eat more normally.

Celiac disease is an autoimmune disorder. If someone with the disease eats gluten — a protein found in wheat, barley and rye — it can damage the small intestine.

The vaccine, dubbed Nexvax2, is designed to elicit an immune system response in about 90 percent of people with celiac disease — specifically those who carry a gene that allows their immune system to “see” the vaccine.

“People with celiac disease often are afraid of food. Nexvax2 will give them freedom to be able to live life and not be afraid of eating out. It will be socially liberating,” said Leslie Williams, CEO of ImmusanT, the company developing the vaccine.

Eating a gluten-free diet isn’t easy, according to Alice Bast, CEO of Beyond Celiac, a nonprofit research organization. Cross contamination with foods containing gluten is always a concern, she explained.

“Because people with celiac disease note that their toughest challenges are when dining out, socializing and traveling, an effective treatment could bring back some of the freedoms people in our community have lost,” Bast said.

“If [Nexvax2] is effective, it may one day be used to enable people with celiac disease to eat a normal diet that contains gluten without damaging their system or getting sick,” she said.

About 1 percent of Americans have celiac disease. Symptoms include stomach pain and bloating, diarrhea, vomiting, constipation, weight loss, fatigue, and delayed growth and puberty. Long-term problems can include malnutrition and nervous system problems.

The current treatment is avoiding gluten. But gluten is found in many foods and products such as lipstick. Even foods that don’t directly contain gluten may be contaminated by gluten during the production process. Something as simple as a gluten-free chicken cutlet being fried in a pan previously used to cook a breaded (containing gluten) chicken cutlet may cause damage to someone with celiac disease, Bast explained.

Williams said that inadvertent gluten exposures like that occur an average of three to four times a month.

Nexvax2 works by reprogramming the T cells in the immune system that attack the small intestine in people with celiac disease. The injectable vaccine makes these cells nonresponsive to gluten exposure, Williams said.

The maintenance injections can be given at home with a device that automatically injects the vaccine under the skin. Williams said people would likely need to give themselves a shot once a week to protect themselves from inadvertent gluten exposures.

ImmusanT has completed five phase 1 trials of Nexvax2, Williams said. Early trials caused patients to vomit, so the initial vaccine dose was lowered. Then it’s slowly increased until people are exposed to an amount of gluten that’s about equivalent to two loaves of bread.

Williams said the vaccine was safe and well-tolerated in the early trials. Because it affects a specific part of the immune system, she said there aren’t concerns about immune system suppression.

“The vaccine targets only the part of the immune system that leads to celiac disease complications throughout the body. Unlike immunotherapy treatments for cancer, rheumatoid arthritis and inflammatory bowel disease, Nexvax2 does not suppress the whole immune system,” Bast said.

ImmusanT is planning a six-month phase 2 study on the vaccine. It will include 150 people with celiac disease from 40 sites in the United States, Australia and New Zealand, Williams noted. She said it’s too soon to predict right now when the vaccine might potentially be available. It’s also too soon to estimate the cost, she said.

Bast said that Nexvax2 isn’t the only possible treatment for celiac disease in development.

“There are more than a dozen therapies in the research pipeline. Nexvax2 is one of three therapeutic vaccines under investigation. Other approaches include preventing gluten from being absorbed by the body, breaking the gluten down using enzymes, and managing the body’s reaction to gluten after it is absorbed,” Bast said.

More information

The Celiac Disease Foundation offers more on celiac disease.

© 2018 HealthDay. All rights reserved.

Posted: November 2018

Tagged with:

About author

Related Articles